ZimVie stockholders approve acquisition by ARCHIMED affiliate

PALM BEACH GARDENS, Fla. - ZimVie Inc. (NASDAQ:ZIMV) announced Friday that its stockholders have voted to approve the company’s acquisition by an affiliate of healthcare investment firm ARCHIMED. According to InvestingPro data, ZimVie has seen remarkable momentum, with its stock surging over 108% in the past six months.

The approval came during a special stockholder meeting held on Friday. The transaction is expected to close on October 20, 2025, pending satisfaction of all conditions outlined in the merger agreement signed on July 20, 2025.

ZimVie, a dental implant market company headquartered in Palm Beach Gardens, Florida, develops and manufactures products supporting dental tooth replacement and restoration procedures. The company offers dental implants, biomaterials, and digital workflow solutions. With annual revenue of $443.4 million and a strong gross profit margin of 65.3%, ZimVie maintains a healthy financial position, as evidenced by its current ratio of 2.37.

ARCHIMED, which has offices across Europe, North America, and Asia, is an investment firm focused exclusively on healthcare industries. The firm manages approximately €8 billion across various funds.

The acquisition was first announced in July when the companies entered into the merger agreement. Financial terms of the transaction were not disclosed in the press release statement.

The merger remains subject to customary closing conditions as specified in the agreement between the parties.

ZimVie currently trades on the Nasdaq stock exchange under the ticker symbol ZIMV. The stock is trading near its 52-week high of $19.01, with a market capitalization of $534 million. Discover more detailed insights and analysis with InvestingPro, which offers comprehensive financial metrics and expert research reports for over 1,400 US stocks.

In other recent news, ZimVie Inc. reported its second-quarter 2025 results, showcasing revenue of $116.7 million. This figure surpassed both B.Riley’s and consensus estimates, which stood at $112.6 million and $112.8 million respectively. Additionally, the company’s adjusted EBITDA reached $17.5 million, exceeding analyst expectations of $17.2 million. ZimVie also announced a definitive agreement to be acquired by healthcare investment firm ARCHIMED in a deal valued at approximately $730 million. Under the terms of this agreement, ZimVie stockholders will receive $19.00 in cash per share. Barclays responded to this merger announcement by upgrading ZimVie’s stock rating from Underweight to Equalweight and increased its price target to $19.00. Furthermore, ZimVie revealed a strategic distribution agreement with Osstem Implant Co., Ltd. to expand its presence in the Chinese dental implant market. This partnership grants Osstem Implant exclusive commercial responsibility for ZimVie implant systems within China. Lastly, B.Riley downgraded ZimVie’s stock rating from Buy to Neutral, despite raising its price target to $19.00, following the acquisition news.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.